Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2321)	3/17/2008 3:32:36 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

QLTI Is up 34.69% on volume of 2,937,502 > 10x its ADV. bigcharts.marketwatch.com It announced today that the FDA completed its review its labeling supplement for Aczone & has removed the G6PD screening & blood monitoring requirements. QLTI completed a PIV last year in patients with G6PD & it demonstrated no evidence of hemolytic anemia in that patient population. Aczone was approved for sale on Jul 2005. The PIV clinical trial of the product was performed to meet a post-approval commitment requested by the FDA. The stock is trying to get off its longer term DT coming from the Feb 2007 H at $9.92 bigcharts.marketwatch.com The stock trades around 0.8xBV with no significant LTD & +CF close to $0.30 The short ratio is > 5x its ADV The Apr 2004 H was $30.70, the Augn 201 H $81.94 & the Jan 2000 H $85.75 <g> bigcharts.marketwatch.com Bernard